Skip to main content

AccessPak for HIV PEP Expanded with Viracept Side Effects

Generic name: emtricitabine / nelfinavir / tenofovir

Note: This document contains side effect information about emtricitabine / nelfinavir / tenofovir. Some dosage forms listed on this page may not apply to the brand name AccessPak for HIV PEP Expanded with Viracept.

Applies to emtricitabine / nelfinavir / tenofovir: oral kit.

You should not take this medicine if you have severe liver or kidney disease. Do not take with other medicines that contain emtricitabine, tenofovir, or lamivudine.

This medicine is sometimes used to reduce the risk of becoming infected with HIV. You must be HIV-negative to use emtricitabine, nelfinavir, and tenofovir for this purpose.

Tell your doctor about all your current medicines and any you start or stop using. Many drugs can interact, and some drugs should not be used together.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Mild symptoms of lactic acidosis may worsen over time, and this condition can be fatal. Get emergency medical help if you have: unusual muscle pain, trouble breathing, stomach pain, vomiting, fast/slow or irregular heartbeats, dizziness, feeling cold, or feeling very weak or tired.

Call your doctor at once if you have:

This medicine affects your immune system, which may cause certain side effects (even weeks or months after you've taken this medicine). Tell your doctor if you have:

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

More about AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir)

Patient resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.